nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—CYP2D6—Parkinson's disease	0.265	0.583	CbGaD
Sorafenib—ABCB1—Parkinson's disease	0.189	0.417	CbGaD
Sorafenib—Regorafenib—ABL1—Parkinson's disease	0.00607	0.751	CrCbGaD
Sorafenib—HIPK3—cardiovascular system—Parkinson's disease	0.00132	0.00629	CbGeAlD
Sorafenib—MAPK15—brain—Parkinson's disease	0.00132	0.00625	CbGeAlD
Sorafenib—KIT—hindbrain—Parkinson's disease	0.00127	0.00605	CbGeAlD
Sorafenib—TIE1—cardiovascular system—Parkinson's disease	0.00124	0.00588	CbGeAlD
Sorafenib—RET—embryo—Parkinson's disease	0.00121	0.00573	CbGeAlD
Sorafenib—FLT3—cardiovascular system—Parkinson's disease	0.00112	0.00535	CbGeAlD
Sorafenib—Regorafenib—ABCB1—Parkinson's disease	0.00112	0.139	CrCbGaD
Sorafenib—MAPK11—head—Parkinson's disease	0.00108	0.00512	CbGeAlD
Sorafenib—FLT1—embryo—Parkinson's disease	0.00106	0.00505	CbGeAlD
Sorafenib—CDK7—head—Parkinson's disease	0.00106	0.00503	CbGeAlD
Sorafenib—RAF1—embryo—Parkinson's disease	0.00106	0.00502	CbGeAlD
Sorafenib—AURKC—head—Parkinson's disease	0.00104	0.00496	CbGeAlD
Sorafenib—FLT4—cardiovascular system—Parkinson's disease	0.00102	0.00486	CbGeAlD
Sorafenib—MAPK11—nervous system—Parkinson's disease	0.00102	0.00485	CbGeAlD
Sorafenib—CDK7—nervous system—Parkinson's disease	0.001	0.00477	CbGeAlD
Sorafenib—PDGFRA—embryo—Parkinson's disease	0.000995	0.00473	CbGeAlD
Sorafenib—AURKC—nervous system—Parkinson's disease	0.000988	0.0047	CbGeAlD
Sorafenib—RALBP1—forebrain—Parkinson's disease	0.000988	0.00469	CbGeAlD
Sorafenib—MAPK11—central nervous system—Parkinson's disease	0.000983	0.00467	CbGeAlD
Sorafenib—RAF1—brainstem—Parkinson's disease	0.000968	0.0046	CbGeAlD
Sorafenib—CDK7—central nervous system—Parkinson's disease	0.000967	0.0046	CbGeAlD
Sorafenib—EPHA6—head—Parkinson's disease	0.000965	0.00459	CbGeAlD
Sorafenib—MAPK11—cerebellum—Parkinson's disease	0.00096	0.00457	CbGeAlD
Sorafenib—AURKC—central nervous system—Parkinson's disease	0.000952	0.00452	CbGeAlD
Sorafenib—CDK7—cerebellum—Parkinson's disease	0.000945	0.00449	CbGeAlD
Sorafenib—TAOK2—cerebellum—Parkinson's disease	0.000937	0.00446	CbGeAlD
Sorafenib—RAF1—forebrain—Parkinson's disease	0.000934	0.00444	CbGeAlD
Sorafenib—EPHB6—forebrain—Parkinson's disease	0.000928	0.00441	CbGeAlD
Sorafenib—BRAF—midbrain—Parkinson's disease	0.000926	0.0044	CbGeAlD
Sorafenib—MKNK2—cardiovascular system—Parkinson's disease	0.000925	0.0044	CbGeAlD
Sorafenib—EPHA6—nervous system—Parkinson's disease	0.000915	0.00435	CbGeAlD
Sorafenib—ZAK—head—Parkinson's disease	0.000915	0.00435	CbGeAlD
Sorafenib—MKNK1—cardiovascular system—Parkinson's disease	0.000913	0.00434	CbGeAlD
Sorafenib—KDR—embryo—Parkinson's disease	0.000898	0.00427	CbGeAlD
Sorafenib—Vismodegib—ABCB1—Parkinson's disease	0.00089	0.11	CrCbGaD
Sorafenib—HIPK4—brain—Parkinson's disease	0.000885	0.00421	CbGeAlD
Sorafenib—EPHA6—central nervous system—Parkinson's disease	0.000881	0.00419	CbGeAlD
Sorafenib—PDGFRA—forebrain—Parkinson's disease	0.00088	0.00418	CbGeAlD
Sorafenib—MAP3K19—head—Parkinson's disease	0.000877	0.00417	CbGeAlD
Sorafenib—CSF1R—embryo—Parkinson's disease	0.000876	0.00417	CbGeAlD
Sorafenib—ZAK—nervous system—Parkinson's disease	0.000868	0.00413	CbGeAlD
Sorafenib—FGFR1—medulla oblongata—Parkinson's disease	0.000861	0.00409	CbGeAlD
Sorafenib—TIE1—head—Parkinson's disease	0.000837	0.00398	CbGeAlD
Sorafenib—ZAK—central nervous system—Parkinson's disease	0.000835	0.00397	CbGeAlD
Sorafenib—RALBP1—cardiovascular system—Parkinson's disease	0.000835	0.00397	CbGeAlD
Sorafenib—MAP3K19—nervous system—Parkinson's disease	0.000832	0.00396	CbGeAlD
Sorafenib—MAP2K5—brainstem—Parkinson's disease	0.000823	0.00391	CbGeAlD
Sorafenib—ZAK—cerebellum—Parkinson's disease	0.000817	0.00388	CbGeAlD
Sorafenib—MAP3K7—medulla oblongata—Parkinson's disease	0.000815	0.00388	CbGeAlD
Sorafenib—MAP3K19—central nervous system—Parkinson's disease	0.000801	0.00381	CbGeAlD
Sorafenib—HIPK3—cerebellum—Parkinson's disease	0.000799	0.0038	CbGeAlD
Sorafenib—KIT—embryo—Parkinson's disease	0.000796	0.00378	CbGeAlD
Sorafenib—FLT1—cardiovascular system—Parkinson's disease	0.000794	0.00378	CbGeAlD
Sorafenib—KDR—forebrain—Parkinson's disease	0.000794	0.00377	CbGeAlD
Sorafenib—TIE1—nervous system—Parkinson's disease	0.000794	0.00377	CbGeAlD
Sorafenib—MKNK2—medulla oblongata—Parkinson's disease	0.00079	0.00376	CbGeAlD
Sorafenib—RAF1—cardiovascular system—Parkinson's disease	0.00079	0.00375	CbGeAlD
Sorafenib—FGFR1—midbrain—Parkinson's disease	0.000787	0.00374	CbGeAlD
Sorafenib—MKNK1—medulla oblongata—Parkinson's disease	0.00078	0.00371	CbGeAlD
Sorafenib—MAPK11—brain—Parkinson's disease	0.00078	0.00371	CbGeAlD
Sorafenib—PDGFRB—embryo—Parkinson's disease	0.000777	0.00369	CbGeAlD
Sorafenib—CSF1R—forebrain—Parkinson's disease	0.000775	0.00368	CbGeAlD
Sorafenib—RET—medulla oblongata—Parkinson's disease	0.000771	0.00366	CbGeAlD
Sorafenib—FGFR1—spinal cord—Parkinson's disease	0.000768	0.00365	CbGeAlD
Sorafenib—CDK7—brain—Parkinson's disease	0.000767	0.00365	CbGeAlD
Sorafenib—TIE1—central nervous system—Parkinson's disease	0.000764	0.00363	CbGeAlD
Sorafenib—TAOK2—brain—Parkinson's disease	0.000761	0.00362	CbGeAlD
Sorafenib—AURKC—brain—Parkinson's disease	0.000755	0.00359	CbGeAlD
Sorafenib—STK10—cardiovascular system—Parkinson's disease	0.000752	0.00357	CbGeAlD
Sorafenib—TIE1—cerebellum—Parkinson's disease	0.000747	0.00355	CbGeAlD
Sorafenib—MAP3K7—midbrain—Parkinson's disease	0.000745	0.00354	CbGeAlD
Sorafenib—PDGFRA—cardiovascular system—Parkinson's disease	0.000744	0.00354	CbGeAlD
Sorafenib—KIT—brainstem—Parkinson's disease	0.000729	0.00347	CbGeAlD
Sorafenib—MAP3K7—spinal cord—Parkinson's disease	0.000727	0.00346	CbGeAlD
Sorafenib—MKNK2—midbrain—Parkinson's disease	0.000722	0.00343	CbGeAlD
Sorafenib—BRAF—cerebellum—Parkinson's disease	0.000716	0.0034	CbGeAlD
Sorafenib—RALBP1—medulla oblongata—Parkinson's disease	0.000713	0.00339	CbGeAlD
Sorafenib—MKNK1—midbrain—Parkinson's disease	0.000713	0.00339	CbGeAlD
Sorafenib—MKNK2—spinal cord—Parkinson's disease	0.000705	0.00335	CbGeAlD
Sorafenib—RET—midbrain—Parkinson's disease	0.000704	0.00335	CbGeAlD
Sorafenib—EPHA6—brain—Parkinson's disease	0.0007	0.00333	CbGeAlD
Sorafenib—MKNK1—spinal cord—Parkinson's disease	0.000696	0.00331	CbGeAlD
Sorafenib—FLT4—head—Parkinson's disease	0.000692	0.00329	CbGeAlD
Sorafenib—RET—spinal cord—Parkinson's disease	0.000687	0.00327	CbGeAlD
Sorafenib—EPHX2—cerebellum—Parkinson's disease	0.000684	0.00325	CbGeAlD
Sorafenib—FLT3—cerebellum—Parkinson's disease	0.000679	0.00323	CbGeAlD
Sorafenib—FLT1—medulla oblongata—Parkinson's disease	0.000679	0.00323	CbGeAlD
Sorafenib—RAF1—medulla oblongata—Parkinson's disease	0.000675	0.00321	CbGeAlD
Sorafenib—KDR—cardiovascular system—Parkinson's disease	0.000671	0.00319	CbGeAlD
Sorafenib—MAP2K5—cardiovascular system—Parkinson's disease	0.000671	0.00319	CbGeAlD
Sorafenib—EPHB6—medulla oblongata—Parkinson's disease	0.000671	0.00319	CbGeAlD
Sorafenib—ZAK—brain—Parkinson's disease	0.000663	0.00315	CbGeAlD
Sorafenib—CSF1R—cardiovascular system—Parkinson's disease	0.000655	0.00312	CbGeAlD
Sorafenib—RALBP1—midbrain—Parkinson's disease	0.000652	0.0031	CbGeAlD
Sorafenib—HIPK3—brain—Parkinson's disease	0.000649	0.00309	CbGeAlD
Sorafenib—RALBP1—spinal cord—Parkinson's disease	0.000636	0.00302	CbGeAlD
Sorafenib—MAP3K19—brain—Parkinson's disease	0.000636	0.00302	CbGeAlD
Sorafenib—MKNK2—head—Parkinson's disease	0.000626	0.00298	CbGeAlD
Sorafenib—FLT1—midbrain—Parkinson's disease	0.00062	0.00295	CbGeAlD
Sorafenib—MKNK1—head—Parkinson's disease	0.000618	0.00294	CbGeAlD
Sorafenib—RAF1—midbrain—Parkinson's disease	0.000617	0.00293	CbGeAlD
Sorafenib—EPHB6—midbrain—Parkinson's disease	0.000613	0.00291	CbGeAlD
Sorafenib—RET—head—Parkinson's disease	0.000611	0.0029	CbGeAlD
Sorafenib—FGFR1—cerebellum—Parkinson's disease	0.000609	0.00289	CbGeAlD
Sorafenib—TIE1—brain—Parkinson's disease	0.000607	0.00288	CbGeAlD
Sorafenib—FLT1—spinal cord—Parkinson's disease	0.000605	0.00288	CbGeAlD
Sorafenib—RAF1—spinal cord—Parkinson's disease	0.000602	0.00286	CbGeAlD
Sorafenib—HTR2C—brainstem—Parkinson's disease	0.0006	0.00285	CbGeAlD
Sorafenib—EPHB6—spinal cord—Parkinson's disease	0.000598	0.00284	CbGeAlD
Sorafenib—KIT—cardiovascular system—Parkinson's disease	0.000595	0.00283	CbGeAlD
Sorafenib—MKNK2—nervous system—Parkinson's disease	0.000594	0.00282	CbGeAlD
Sorafenib—MKNK1—nervous system—Parkinson's disease	0.000586	0.00279	CbGeAlD
Sorafenib—BRAF—brain—Parkinson's disease	0.000582	0.00276	CbGeAlD
Sorafenib—PDGFRB—cardiovascular system—Parkinson's disease	0.000581	0.00276	CbGeAlD
Sorafenib—HTR2C—forebrain—Parkinson's disease	0.000579	0.00275	CbGeAlD
Sorafenib—RET—nervous system—Parkinson's disease	0.000579	0.00275	CbGeAlD
Sorafenib—MAP3K7—cerebellum—Parkinson's disease	0.000576	0.00274	CbGeAlD
Sorafenib—KDR—medulla oblongata—Parkinson's disease	0.000574	0.00273	CbGeAlD
Sorafenib—MAP2K5—medulla oblongata—Parkinson's disease	0.000574	0.00273	CbGeAlD
Sorafenib—MKNK2—central nervous system—Parkinson's disease	0.000572	0.00272	CbGeAlD
Sorafenib—PDGFRA—spinal cord—Parkinson's disease	0.000567	0.0027	CbGeAlD
Sorafenib—RALBP1—head—Parkinson's disease	0.000565	0.00269	CbGeAlD
Sorafenib—MKNK1—central nervous system—Parkinson's disease	0.000564	0.00268	CbGeAlD
Sorafenib—CSF1R—medulla oblongata—Parkinson's disease	0.00056	0.00266	CbGeAlD
Sorafenib—MKNK2—cerebellum—Parkinson's disease	0.000559	0.00266	CbGeAlD
Sorafenib—RET—central nervous system—Parkinson's disease	0.000557	0.00265	CbGeAlD
Sorafenib—EPHX2—brain—Parkinson's disease	0.000556	0.00264	CbGeAlD
Sorafenib—MKNK1—cerebellum—Parkinson's disease	0.000552	0.00262	CbGeAlD
Sorafenib—ABCC4—forebrain—Parkinson's disease	0.000547	0.0026	CbGeAlD
Sorafenib—RET—cerebellum—Parkinson's disease	0.000545	0.00259	CbGeAlD
Sorafenib—HTR2B—forebrain—Parkinson's disease	0.000544	0.00259	CbGeAlD
Sorafenib—FLT1—head—Parkinson's disease	0.000538	0.00256	CbGeAlD
Sorafenib—RALBP1—nervous system—Parkinson's disease	0.000536	0.00255	CbGeAlD
Sorafenib—RAF1—head—Parkinson's disease	0.000535	0.00254	CbGeAlD
Sorafenib—EPHB6—head—Parkinson's disease	0.000532	0.00253	CbGeAlD
Sorafenib—MAP2K5—midbrain—Parkinson's disease	0.000524	0.00249	CbGeAlD
Sorafenib—KDR—midbrain—Parkinson's disease	0.000524	0.00249	CbGeAlD
Sorafenib—RALBP1—central nervous system—Parkinson's disease	0.000516	0.00245	CbGeAlD
Sorafenib—CSF1R—midbrain—Parkinson's disease	0.000512	0.00243	CbGeAlD
Sorafenib—KDR—spinal cord—Parkinson's disease	0.000512	0.00243	CbGeAlD
Sorafenib—MAP2K5—spinal cord—Parkinson's disease	0.000512	0.00243	CbGeAlD
Sorafenib—FLT1—nervous system—Parkinson's disease	0.00051	0.00242	CbGeAlD
Sorafenib—STK10—head—Parkinson's disease	0.000509	0.00242	CbGeAlD
Sorafenib—KIT—medulla oblongata—Parkinson's disease	0.000508	0.00242	CbGeAlD
Sorafenib—RAF1—nervous system—Parkinson's disease	0.000507	0.00241	CbGeAlD
Sorafenib—RALBP1—cerebellum—Parkinson's disease	0.000504	0.0024	CbGeAlD
Sorafenib—EPHB6—nervous system—Parkinson's disease	0.000504	0.0024	CbGeAlD
Sorafenib—PDGFRA—head—Parkinson's disease	0.000504	0.0024	CbGeAlD
Sorafenib—FLT4—brain—Parkinson's disease	0.000501	0.00238	CbGeAlD
Sorafenib—CSF1R—spinal cord—Parkinson's disease	0.000499	0.00237	CbGeAlD
Sorafenib—PDGFRB—medulla oblongata—Parkinson's disease	0.000497	0.00236	CbGeAlD
Sorafenib—FGFR1—brain—Parkinson's disease	0.000495	0.00235	CbGeAlD
Sorafenib—FLT1—central nervous system—Parkinson's disease	0.000491	0.00233	CbGeAlD
Sorafenib—RAF1—central nervous system—Parkinson's disease	0.000488	0.00232	CbGeAlD
Sorafenib—EPHB6—central nervous system—Parkinson's disease	0.000485	0.00231	CbGeAlD
Sorafenib—STK10—nervous system—Parkinson's disease	0.000483	0.00229	CbGeAlD
Sorafenib—FLT1—cerebellum—Parkinson's disease	0.00048	0.00228	CbGeAlD
Sorafenib—CYP2D6—hindbrain—Parkinson's disease	0.000479	0.00228	CbGeAlD
Sorafenib—PDGFRA—nervous system—Parkinson's disease	0.000478	0.00227	CbGeAlD
Sorafenib—RAF1—cerebellum—Parkinson's disease	0.000477	0.00227	CbGeAlD
Sorafenib—EPHB6—cerebellum—Parkinson's disease	0.000474	0.00225	CbGeAlD
Sorafenib—MAP3K7—brain—Parkinson's disease	0.000468	0.00223	CbGeAlD
Sorafenib—STK10—central nervous system—Parkinson's disease	0.000465	0.00221	CbGeAlD
Sorafenib—KIT—midbrain—Parkinson's disease	0.000465	0.00221	CbGeAlD
Sorafenib—HTR2B—cardiovascular system—Parkinson's disease	0.00046	0.00219	CbGeAlD
Sorafenib—PDGFRA—central nervous system—Parkinson's disease	0.00046	0.00219	CbGeAlD
Sorafenib—MAP2K5—head—Parkinson's disease	0.000455	0.00216	CbGeAlD
Sorafenib—KDR—head—Parkinson's disease	0.000455	0.00216	CbGeAlD
Sorafenib—STK10—cerebellum—Parkinson's disease	0.000454	0.00216	CbGeAlD
Sorafenib—PDGFRB—midbrain—Parkinson's disease	0.000454	0.00216	CbGeAlD
Sorafenib—MKNK2—brain—Parkinson's disease	0.000454	0.00216	CbGeAlD
Sorafenib—KIT—spinal cord—Parkinson's disease	0.000453	0.00216	CbGeAlD
Sorafenib—PDGFRA—cerebellum—Parkinson's disease	0.00045	0.00214	CbGeAlD
Sorafenib—MKNK1—brain—Parkinson's disease	0.000448	0.00213	CbGeAlD
Sorafenib—CSF1R—head—Parkinson's disease	0.000444	0.00211	CbGeAlD
Sorafenib—PDGFRB—spinal cord—Parkinson's disease	0.000443	0.0021	CbGeAlD
Sorafenib—RET—brain—Parkinson's disease	0.000443	0.0021	CbGeAlD
Sorafenib—KDR—nervous system—Parkinson's disease	0.000431	0.00205	CbGeAlD
Sorafenib—MAP2K5—nervous system—Parkinson's disease	0.000431	0.00205	CbGeAlD
Sorafenib—CSF1R—nervous system—Parkinson's disease	0.000421	0.002	CbGeAlD
Sorafenib—HTR2C—medulla oblongata—Parkinson's disease	0.000419	0.00199	CbGeAlD
Sorafenib—MAP2K5—central nervous system—Parkinson's disease	0.000415	0.00197	CbGeAlD
Sorafenib—KDR—central nervous system—Parkinson's disease	0.000415	0.00197	CbGeAlD
Sorafenib—RALBP1—brain—Parkinson's disease	0.00041	0.00195	CbGeAlD
Sorafenib—MAP2K5—cerebellum—Parkinson's disease	0.000406	0.00193	CbGeAlD
Sorafenib—KDR—cerebellum—Parkinson's disease	0.000406	0.00193	CbGeAlD
Sorafenib—CSF1R—central nervous system—Parkinson's disease	0.000405	0.00193	CbGeAlD
Sorafenib—KIT—head—Parkinson's disease	0.000403	0.00192	CbGeAlD
Sorafenib—CSF1R—cerebellum—Parkinson's disease	0.000396	0.00188	CbGeAlD
Sorafenib—PDGFRB—head—Parkinson's disease	0.000394	0.00187	CbGeAlD
Sorafenib—FLT1—brain—Parkinson's disease	0.00039	0.00185	CbGeAlD
Sorafenib—RAF1—brain—Parkinson's disease	0.000387	0.00184	CbGeAlD
Sorafenib—EPHB6—brain—Parkinson's disease	0.000385	0.00183	CbGeAlD
Sorafenib—HTR2C—midbrain—Parkinson's disease	0.000383	0.00182	CbGeAlD
Sorafenib—KIT—nervous system—Parkinson's disease	0.000382	0.00182	CbGeAlD
Sorafenib—HTR2C—spinal cord—Parkinson's disease	0.000373	0.00177	CbGeAlD
Sorafenib—PDGFRB—nervous system—Parkinson's disease	0.000373	0.00177	CbGeAlD
Sorafenib—STK10—brain—Parkinson's disease	0.000369	0.00175	CbGeAlD
Sorafenib—KIT—central nervous system—Parkinson's disease	0.000368	0.00175	CbGeAlD
Sorafenib—PDGFRA—brain—Parkinson's disease	0.000365	0.00174	CbGeAlD
Sorafenib—KIT—cerebellum—Parkinson's disease	0.000359	0.00171	CbGeAlD
Sorafenib—PDGFRB—central nervous system—Parkinson's disease	0.000359	0.00171	CbGeAlD
Sorafenib—PDGFRB—cerebellum—Parkinson's disease	0.000351	0.00167	CbGeAlD
Sorafenib—HTR2C—head—Parkinson's disease	0.000332	0.00158	CbGeAlD
Sorafenib—KDR—brain—Parkinson's disease	0.000329	0.00157	CbGeAlD
Sorafenib—MAP2K5—brain—Parkinson's disease	0.000329	0.00157	CbGeAlD
Sorafenib—CSF1R—brain—Parkinson's disease	0.000322	0.00153	CbGeAlD
Sorafenib—HTR2C—nervous system—Parkinson's disease	0.000315	0.0015	CbGeAlD
Sorafenib—ABCC4—head—Parkinson's disease	0.000313	0.00149	CbGeAlD
Sorafenib—HTR2B—head—Parkinson's disease	0.000312	0.00148	CbGeAlD
Sorafenib—HTR2C—central nervous system—Parkinson's disease	0.000303	0.00144	CbGeAlD
Sorafenib—CYP2B6—cardiovascular system—Parkinson's disease	0.000301	0.00143	CbGeAlD
Sorafenib—CYP2C9—cardiovascular system—Parkinson's disease	0.000298	0.00142	CbGeAlD
Sorafenib—ABCC4—nervous system—Parkinson's disease	0.000297	0.00141	CbGeAlD
Sorafenib—HTR2B—nervous system—Parkinson's disease	0.000295	0.0014	CbGeAlD
Sorafenib—KIT—brain—Parkinson's disease	0.000292	0.00139	CbGeAlD
Sorafenib—ABCC4—central nervous system—Parkinson's disease	0.000286	0.00136	CbGeAlD
Sorafenib—PDGFRB—brain—Parkinson's disease	0.000285	0.00136	CbGeAlD
Sorafenib—HTR2B—central nervous system—Parkinson's disease	0.000284	0.00135	CbGeAlD
Sorafenib—ABCG2—medulla oblongata—Parkinson's disease	0.000279	0.00133	CbGeAlD
Sorafenib—CYP2D6—brainstem—Parkinson's disease	0.000274	0.0013	CbGeAlD
Sorafenib—CYP2D6—forebrain—Parkinson's disease	0.000265	0.00126	CbGeAlD
Sorafenib—ABCG2—midbrain—Parkinson's disease	0.000255	0.00121	CbGeAlD
Sorafenib—ABCG2—spinal cord—Parkinson's disease	0.000249	0.00118	CbGeAlD
Sorafenib—HTR2C—brain—Parkinson's disease	0.00024	0.00114	CbGeAlD
Sorafenib—ABCC4—brain—Parkinson's disease	0.000227	0.00108	CbGeAlD
Sorafenib—HTR2B—brain—Parkinson's disease	0.000226	0.00107	CbGeAlD
Sorafenib—ABCB1—embryo—Parkinson's disease	0.000215	0.00102	CbGeAlD
Sorafenib—CYP2B6—head—Parkinson's disease	0.000204	0.00097	CbGeAlD
Sorafenib—ABCG2—cerebellum—Parkinson's disease	0.000197	0.000938	CbGeAlD
Sorafenib—CYP2B6—nervous system—Parkinson's disease	0.000193	0.00092	CbGeAlD
Sorafenib—ABCB1—forebrain—Parkinson's disease	0.00019	0.000906	CbGeAlD
Sorafenib—CYP2B6—central nervous system—Parkinson's disease	0.000186	0.000885	CbGeAlD
Sorafenib—CYP2C8—brain—Parkinson's disease	0.000165	0.000784	CbGeAlD
Sorafenib—ABCB1—cardiovascular system—Parkinson's disease	0.000161	0.000766	CbGeAlD
Sorafenib—ABCG2—brain—Parkinson's disease	0.00016	0.000762	CbGeAlD
Sorafenib—CYP2D6—head—Parkinson's disease	0.000152	0.000721	CbGeAlD
Sorafenib—CYP2B6—brain—Parkinson's disease	0.000148	0.000703	CbGeAlD
Sorafenib—CYP3A4—nervous system—Parkinson's disease	0.000146	0.000694	CbGeAlD
Sorafenib—CYP2D6—nervous system—Parkinson's disease	0.000144	0.000683	CbGeAlD
Sorafenib—CYP3A4—central nervous system—Parkinson's disease	0.000141	0.000669	CbGeAlD
Sorafenib—CYP2D6—central nervous system—Parkinson's disease	0.000138	0.000658	CbGeAlD
Sorafenib—ABCB1—medulla oblongata—Parkinson's disease	0.000138	0.000654	CbGeAlD
Sorafenib—CYP2D6—cerebellum—Parkinson's disease	0.000135	0.000643	CbGeAlD
Sorafenib—ABCB1—midbrain—Parkinson's disease	0.000126	0.000598	CbGeAlD
Sorafenib—ABCB1—spinal cord—Parkinson's disease	0.000123	0.000583	CbGeAlD
Sorafenib—CYP2D6—brain—Parkinson's disease	0.00011	0.000522	CbGeAlD
Sorafenib—ABCB1—head—Parkinson's disease	0.000109	0.000519	CbGeAlD
Sorafenib—ABCB1—nervous system—Parkinson's disease	0.000103	0.000492	CbGeAlD
Sorafenib—ABCB1—central nervous system—Parkinson's disease	9.96e-05	0.000473	CbGeAlD
Sorafenib—ABCB1—cerebellum—Parkinson's disease	9.73e-05	0.000463	CbGeAlD
Sorafenib—ABCB1—brain—Parkinson's disease	7.9e-05	0.000376	CbGeAlD
Sorafenib—UGT1A1—Metabolism—APOE—Parkinson's disease	7.48e-06	2.29e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—APOE—Parkinson's disease	7.48e-06	2.29e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL1B—Parkinson's disease	7.47e-06	2.29e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CYP2E1—Parkinson's disease	7.46e-06	2.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—INS—Parkinson's disease	7.42e-06	2.27e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GPX1—Parkinson's disease	7.39e-06	2.26e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NQO1—Parkinson's disease	7.38e-06	2.26e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NGF—Parkinson's disease	7.36e-06	2.25e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HTR2A—Parkinson's disease	7.35e-06	2.25e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GPX1—Parkinson's disease	7.32e-06	2.24e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CYP2E1—Parkinson's disease	7.3e-06	2.23e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—TH—Parkinson's disease	7.27e-06	2.23e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTA4—Parkinson's disease	7.25e-06	2.22e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—MAPK8—Parkinson's disease	7.24e-06	2.22e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—MAPK8—Parkinson's disease	7.24e-06	2.22e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NQO1—Parkinson's disease	7.21e-06	2.21e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	7.2e-06	2.2e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	7.16e-06	2.19e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—TH—Parkinson's disease	7.11e-06	2.18e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HTR2A—Parkinson's disease	7e-06	2.14e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CYCS—Parkinson's disease	6.98e-06	2.14e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP2D6—Parkinson's disease	6.91e-06	2.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NGF—Parkinson's disease	6.88e-06	2.1e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—MAPK8—Parkinson's disease	6.87e-06	2.1e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—MAPK8—Parkinson's disease	6.85e-06	2.1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—INS—Parkinson's disease	6.84e-06	2.09e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—INS—Parkinson's disease	6.84e-06	2.09e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—IL6—Parkinson's disease	6.83e-06	2.09e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—APOE—Parkinson's disease	6.83e-06	2.09e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CYCS—Parkinson's disease	6.83e-06	2.09e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—MTHFR—Parkinson's disease	6.82e-06	2.09e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CTGF—Parkinson's disease	6.78e-06	2.08e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—Parkinson's disease	6.77e-06	2.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IGF2—Parkinson's disease	6.76e-06	2.07e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—MTHFR—Parkinson's disease	6.76e-06	2.07e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CASP3—Parkinson's disease	6.74e-06	2.06e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL1B—Parkinson's disease	6.73e-06	2.06e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CASP3—Parkinson's disease	6.57e-06	2.01e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HTR2A—Parkinson's disease	6.55e-06	2e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IGF1R—Parkinson's disease	6.54e-06	2e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PLA2G6—Parkinson's disease	6.53e-06	2e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—APOE—Parkinson's disease	6.51e-06	1.99e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—INS—Parkinson's disease	6.49e-06	1.99e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—INS—Parkinson's disease	6.48e-06	1.98e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—Parkinson's disease	6.47e-06	1.98e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MAOB—Parkinson's disease	6.46e-06	1.98e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EDN1—Parkinson's disease	6.46e-06	1.98e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—Parkinson's disease	6.43e-06	1.97e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—INS—Parkinson's disease	6.39e-06	1.96e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—INS—Parkinson's disease	6.39e-06	1.96e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—APOE—Parkinson's disease	6.35e-06	1.94e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP2E1—Parkinson's disease	6.32e-06	1.93e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—APOE—Parkinson's disease	6.29e-06	1.93e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NQO1—Parkinson's disease	6.25e-06	1.91e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MAPK8—Parkinson's disease	6.19e-06	1.9e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—COMT—Parkinson's disease	6.18e-06	1.89e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—MAPK8—Parkinson's disease	6.17e-06	1.89e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP2D6—Parkinson's disease	6.17e-06	1.89e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—TH—Parkinson's disease	6.16e-06	1.88e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GSTP1—Parkinson's disease	6.16e-06	1.88e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	6.15e-06	1.88e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MAOA—Parkinson's disease	6.14e-06	1.88e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—APOE—Parkinson's disease	6.09e-06	1.86e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—HMOX1—Parkinson's disease	6.07e-06	1.86e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CTGF—Parkinson's disease	6.05e-06	1.85e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—COMT—Parkinson's disease	6.04e-06	1.85e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MAPK8—Parkinson's disease	6.04e-06	1.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—Parkinson's disease	6.03e-06	1.85e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP2D6—Parkinson's disease	6.02e-06	1.84e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GSTP1—Parkinson's disease	6.02e-06	1.84e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MAOA—Parkinson's disease	6e-06	1.84e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1B—Parkinson's disease	6e-06	1.84e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NGF—Parkinson's disease	5.94e-06	1.82e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—HMOX1—Parkinson's disease	5.93e-06	1.82e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—DDC—Parkinson's disease	5.93e-06	1.81e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYCS—Parkinson's disease	5.91e-06	1.81e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CTGF—Parkinson's disease	5.91e-06	1.81e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—INS—Parkinson's disease	5.83e-06	1.79e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ABCB1—Parkinson's disease	5.83e-06	1.78e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—Parkinson's disease	5.79e-06	1.77e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ABCB1—Parkinson's disease	5.69e-06	1.74e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GSTM1—Parkinson's disease	5.66e-06	1.73e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HTR2A—Parkinson's disease	5.65e-06	1.73e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CASP3—Parkinson's disease	5.65e-06	1.73e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP2E1—Parkinson's disease	5.64e-06	1.73e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP2D6—Parkinson's disease	5.62e-06	1.72e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTA4—Parkinson's disease	5.6e-06	1.71e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CASP3—Parkinson's disease	5.6e-06	1.71e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NQO1—Parkinson's disease	5.58e-06	1.71e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CTGF—Parkinson's disease	5.57e-06	1.7e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—INS—Parkinson's disease	5.56e-06	1.7e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GSTM1—Parkinson's disease	5.53e-06	1.69e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CTGF—Parkinson's disease	5.52e-06	1.69e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP2E1—Parkinson's disease	5.5e-06	1.68e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MAPK8—Parkinson's disease	5.5e-06	1.68e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TH—Parkinson's disease	5.5e-06	1.68e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NQO1—Parkinson's disease	5.44e-06	1.67e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—INS—Parkinson's disease	5.42e-06	1.66e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GPX1—Parkinson's disease	5.42e-06	1.66e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—INS—Parkinson's disease	5.38e-06	1.65e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TH—Parkinson's disease	5.36e-06	1.64e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GPX1—Parkinson's disease	5.29e-06	1.62e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYCS—Parkinson's disease	5.28e-06	1.61e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—APOE—Parkinson's disease	5.25e-06	1.61e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—COMT—Parkinson's disease	5.24e-06	1.6e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GSTP1—Parkinson's disease	5.21e-06	1.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—INS—Parkinson's disease	5.2e-06	1.59e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MAOA—Parkinson's disease	5.2e-06	1.59e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MAPK8—Parkinson's disease	5.19e-06	1.59e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	5.19e-06	1.59e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYCS—Parkinson's disease	5.15e-06	1.58e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP2E1—Parkinson's disease	5.14e-06	1.57e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MAPK8—Parkinson's disease	5.14e-06	1.57e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—HMOX1—Parkinson's disease	5.14e-06	1.57e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NQO1—Parkinson's disease	5.13e-06	1.57e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—Parkinson's disease	5.13e-06	1.57e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CASP3—Parkinson's disease	5.09e-06	1.56e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CASP3—Parkinson's disease	5.09e-06	1.56e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NQO1—Parkinson's disease	5.08e-06	1.56e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TH—Parkinson's disease	5.06e-06	1.55e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	5.04e-06	1.54e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TH—Parkinson's disease	5.01e-06	1.53e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MTHFR—Parkinson's disease	5e-06	1.53e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MAOB—Parkinson's disease	4.99e-06	1.53e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ABCB1—Parkinson's disease	4.93e-06	1.51e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MTHFR—Parkinson's disease	4.89e-06	1.5e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYCS—Parkinson's disease	4.85e-06	1.49e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CASP3—Parkinson's disease	4.83e-06	1.48e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CASP3—Parkinson's disease	4.82e-06	1.48e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYCS—Parkinson's disease	4.81e-06	1.47e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP2D6—Parkinson's disease	4.8e-06	1.47e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GSTM1—Parkinson's disease	4.79e-06	1.47e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CTGF—Parkinson's disease	4.72e-06	1.44e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—Parkinson's disease	4.69e-06	1.44e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK8—Parkinson's disease	4.68e-06	1.43e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK8—Parkinson's disease	4.68e-06	1.43e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—COMT—Parkinson's disease	4.67e-06	1.43e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—APOE—Parkinson's disease	4.65e-06	1.42e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTP1—Parkinson's disease	4.65e-06	1.42e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MAOA—Parkinson's disease	4.64e-06	1.42e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—Parkinson's disease	4.62e-06	1.41e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—Parkinson's disease	4.62e-06	1.41e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—HMOX1—Parkinson's disease	4.59e-06	1.4e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GPX1—Parkinson's disease	4.59e-06	1.4e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—COMT—Parkinson's disease	4.56e-06	1.4e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—APOE—Parkinson's disease	4.55e-06	1.39e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTP1—Parkinson's disease	4.54e-06	1.39e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MAOA—Parkinson's disease	4.53e-06	1.39e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—INS—Parkinson's disease	4.49e-06	1.37e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—HMOX1—Parkinson's disease	4.48e-06	1.37e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK8—Parkinson's disease	4.44e-06	1.36e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK8—Parkinson's disease	4.43e-06	1.36e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ABCB1—Parkinson's disease	4.4e-06	1.35e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP2E1—Parkinson's disease	4.39e-06	1.34e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—Parkinson's disease	4.39e-06	1.34e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—Parkinson's disease	4.38e-06	1.34e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NQO1—Parkinson's disease	4.35e-06	1.33e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CASP3—Parkinson's disease	4.34e-06	1.33e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—COMT—Parkinson's disease	4.3e-06	1.32e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TH—Parkinson's disease	4.28e-06	1.31e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTP1—Parkinson's disease	4.28e-06	1.31e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTM1—Parkinson's disease	4.27e-06	1.31e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—Parkinson's disease	4.27e-06	1.31e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MAOA—Parkinson's disease	4.27e-06	1.31e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—COMT—Parkinson's disease	4.26e-06	1.3e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTP1—Parkinson's disease	4.24e-06	1.3e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MTHFR—Parkinson's disease	4.23e-06	1.3e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MAOA—Parkinson's disease	4.23e-06	1.29e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—HMOX1—Parkinson's disease	4.22e-06	1.29e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HMOX1—Parkinson's disease	4.18e-06	1.28e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTM1—Parkinson's disease	4.17e-06	1.28e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CASP3—Parkinson's disease	4.14e-06	1.27e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—Parkinson's disease	4.12e-06	1.26e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYCS—Parkinson's disease	4.11e-06	1.26e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GPX1—Parkinson's disease	4.09e-06	1.25e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—Parkinson's disease	4.05e-06	1.24e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ABCB1—Parkinson's disease	4.05e-06	1.24e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—Parkinson's disease	4.04e-06	1.24e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ABCB1—Parkinson's disease	4.01e-06	1.23e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GPX1—Parkinson's disease	4e-06	1.22e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK8—Parkinson's disease	3.99e-06	1.22e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—INS—Parkinson's disease	3.98e-06	1.22e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—Parkinson's disease	3.96e-06	1.21e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—Parkinson's disease	3.94e-06	1.21e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOE—Parkinson's disease	3.94e-06	1.21e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTM1—Parkinson's disease	3.93e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTM1—Parkinson's disease	3.9e-06	1.19e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—INS—Parkinson's disease	3.89e-06	1.19e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—Parkinson's disease	3.87e-06	1.18e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—Parkinson's disease	3.85e-06	1.18e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—Parkinson's disease	3.85e-06	1.18e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK8—Parkinson's disease	3.81e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—Parkinson's disease	3.78e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GPX1—Parkinson's disease	3.76e-06	1.15e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GPX1—Parkinson's disease	3.73e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	3.71e-06	1.13e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—Parkinson's disease	3.69e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—COMT—Parkinson's disease	3.64e-06	1.11e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—Parkinson's disease	3.64e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CTGF—Parkinson's disease	3.64e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTP1—Parkinson's disease	3.62e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MAOA—Parkinson's disease	3.62e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HMOX1—Parkinson's disease	3.57e-06	1.09e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK8—Parkinson's disease	3.56e-06	1.09e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOE—Parkinson's disease	3.52e-06	1.08e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—Parkinson's disease	3.51e-06	1.08e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—Parkinson's disease	3.47e-06	1.06e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—Parkinson's disease	3.44e-06	1.05e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOE—Parkinson's disease	3.43e-06	1.05e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCB1—Parkinson's disease	3.43e-06	1.05e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	3.39e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—INS—Parkinson's disease	3.37e-06	1.03e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NQO1—Parkinson's disease	3.35e-06	1.03e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—Parkinson's disease	3.34e-06	1.02e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—Parkinson's disease	3.33e-06	1.02e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—Parkinson's disease	3.32e-06	1.02e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—Parkinson's disease	3.31e-06	1.01e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TH—Parkinson's disease	3.31e-06	1.01e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—Parkinson's disease	3.28e-06	1e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—Parkinson's disease	3.24e-06	9.93e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOE—Parkinson's disease	3.23e-06	9.9e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOE—Parkinson's disease	3.21e-06	9.81e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GPX1—Parkinson's disease	3.19e-06	9.76e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYCS—Parkinson's disease	3.17e-06	9.71e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK8—Parkinson's disease	3.07e-06	9.4e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—INS—Parkinson's disease	3e-06	9.19e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—Parkinson's disease	2.99e-06	9.15e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—Parkinson's disease	2.99e-06	9.15e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—Parkinson's disease	2.94e-06	9.01e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—INS—Parkinson's disease	2.93e-06	8.97e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—Parkinson's disease	2.84e-06	8.68e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—Parkinson's disease	2.83e-06	8.66e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—COMT—Parkinson's disease	2.81e-06	8.6e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTP1—Parkinson's disease	2.8e-06	8.56e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MAOA—Parkinson's disease	2.79e-06	8.54e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—INS—Parkinson's disease	2.76e-06	8.46e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMOX1—Parkinson's disease	2.76e-06	8.44e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOE—Parkinson's disease	2.74e-06	8.39e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—INS—Parkinson's disease	2.74e-06	8.38e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCB1—Parkinson's disease	2.65e-06	8.1e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—Parkinson's disease	2.57e-06	7.87e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—Parkinson's disease	2.55e-06	7.8e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GPX1—Parkinson's disease	2.46e-06	7.53e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—Parkinson's disease	2.43e-06	7.44e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—INS—Parkinson's disease	2.34e-06	7.16e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—Parkinson's disease	2.27e-06	6.95e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—Parkinson's disease	2.27e-06	6.95e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOE—Parkinson's disease	2.11e-06	6.47e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—Parkinson's disease	1.96e-06	6e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—INS—Parkinson's disease	1.81e-06	5.53e-06	CbGpPWpGaD
